GSK Settles Zantac Lawsuits For $2.2 Billion
GSK plc (LSE/NYSE: GSK) announced on October 9, 2024 that it has reached agreements with 10 plaintiff firms who together represent 93% (approximately 80,000) of the Zantac (ranitidine) state court product liability cases pending against GSK in the United States. Under these agreements, GSK will make[...]